Millions of people with chronic knee pain have hoped that cannabis and opioids for pain might work better together. A new clinical trial published in Anesthesiology has challenged that idea. The research found no meaningful benefit from combining the two drugs. In some cases, the combination made things worse.
What the Study Found About Cannabis and Opioids for Pain
Researchers at Johns Hopkins University School of Medicine ran a rigorous, double-blind, randomised, placebo-controlled trial. They enrolled 21 adults with diagnosed knee osteoarthritis. Each participant attended four sessions, at least seven days apart. Every session involved a different drug combination: placebo only, the opioid hydromorphone (2mg) alone, the synthetic cannabinoid dronabinol (10mg) alone, or hydromorphone and dronabinol together.
The team measured a wide range of outcomes. These included sensitivity to pressure, heat and cold, self-reported pain scores, walking and stair-climbing ability, cognitive function, and side effects.
The results were straightforward. Neither the cannabinoid and opioid combination nor either drug alone produced meaningful pain relief. Hydromorphone raised the pressure pain threshold above dronabinol’s level. It also reduced mechanical pain sensitisation compared with placebo. But participants’ own knee pain ratings did not improve significantly under any condition.
Side Effects Increased Without Pain Relief
The combined condition raised real concerns about tolerability. Participants who took cannabis and opioids for pain together reported higher nausea, stronger feelings of being “high,” and slower working memory reaction times. None of this came with added pain relief.
“Our study suggests that isn’t the case and patients may experience more side effects when the drugs are combined,” said lead author Dr Katrina R. Hamilton of Ohio University and Johns Hopkins School of Medicine.
Growing numbers of people now combine cannabis with prescription painkillers. Many believe the approach is safer or more effective. This trial found no evidence to support that belief.
Why Preclinical Findings Did Not Translate to Humans
Animal studies long suggested that cannabinoids could boost the pain-relieving power of opioids. The theory was that patients might need lower opioid doses, which would reduce addiction risk. Interest in cannabis and opioids for pain grew steadily, driven by shifting legal landscapes and an ongoing opioid crisis. In the United States alone, opioid overdoses contributed to more than 80,000 deaths in a single recent year.
Yet human trials have consistently failed to replicate those animal findings. The Johns Hopkins team ran a similar trial earlier using a 4mg dose of hydromorphone. That study also found minimal added benefit from combining the two drugs. In that version, researchers recorded adverse events in 35.1% of all sessions. The highest rates occurred when participants took hydromorphone alone or alongside dronabinol. The current study dropped the dose to 2mg to test whether tolerability improved. Adverse events fell to 28.6% of sessions. Still, no significant differences emerged between the four drug conditions.
Cognition: A Mixed Picture for the Cannabinoid and Opioid Combination
Researchers flagged one unexpected finding worth watching. Hydromorphone alone impaired working memory accuracy more than every other condition. The cannabinoid and opioid combination slowed reaction times but did not hurt accuracy as much. The authors speculate that dronabinol might partially protect cognitive function when taken with an opioid. They stressed this remains highly preliminary and needs further study.
Researchers found no significant differences across conditions for fine motor movement, physical functioning, or measures of extramedical drug use risk.
Key Limitations to Consider
The trial was small. Only 21 participants completed all four sessions. The study used a single oral dose of synthetic THC rather than inhaled or full-spectrum cannabis. Most real-world users do not take cannabis this way. Inhaled cannabis reaches peak concentration in 3 to 10 minutes. The oral route used here takes one to two hours. Natural cannabis also contains more than 500 compounds. The synthetic version used in the study contains only pure THC, which may affect outcomes in ways not yet understood.
An editorial published alongside the study noted that participants had never used cannabis before. They also received a relatively high single dose. Both factors may limit how broadly these findings apply to everyday users.
What This Means for Using Cannabis and Opioids for Pain
The study adds to a body of controlled trial evidence. It consistently shows that the cannabinoid and opioid combination does not perform as hoped when tested in real patients with chronic pain. The preclinical promise simply has not carried through to clinical settings.
Patients and clinicians in areas where medical cannabis is legal should weigh this evidence carefully. Combining cannabis and opioids for pain in knee osteoarthritis currently lacks strong clinical justification. The side effect burden is real, and the benefits are not.
Future research should test different cannabis formulations, varied routes of administration, dose-ranging designs, and longer follow-up periods. Until that work arrives, the combination remains more risk than reward for most knee arthritis patients.
(Source: WRD News)